Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL 7 14 versus NORLUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL 7 14 versus NORLUTATE.
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14) vs NORLUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a progestin that suppresses gonadotropin release, preventing ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further inhibiting ovulation. The combination also alters cervical mucus and endometrial lining to impede fertilization and implantation.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 21 days (7 active tablets of norethindrone 0.5 mg/ethinyl estradiol 35 mcg followed by 14 active tablets of norethindrone 1 mg/ethinyl estradiol 35 mcg). Start on day 1 of menstrual cycle.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
None Documented
None Documented
Norethindrone: 8-11 hours; Ethinyl estradiol: 17-27 hours. Achieves steady state within 5-10 days, permitting once-daily dosing.
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
Norethindrone: ~50% renal, ~50% fecal; Ethinyl estradiol: ~50% renal, ~50% fecal, with enterohepatic circulation.
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Category D/X
Category C
Progestin
Progestin